Drug evaluation: OPT-80, a narrow-spectrum macrocyclic antibiotic.

Abstract

Optimer Pharmaceuticals Inc, in collaboration with Par Pharmaceutical Companies Inc, is developing OPT-80, a narrow-spectrum macrocyclic antibiotic secreted by the actinomycete Dactylosporangium aurantiacum, for the potential treatment of Clostridium difficile-associated diarrhea (CDAD) and vancomycin-resistant Enterococcus infection. A phase IIb/III clinical trial of OPT-80 in patients with CDAD is underway.

• Authors: Alan P Johnson
• Journal: Current opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 8 Issue 2 Pg. 168-73 (Feb 2007) ISSN: 1472-4472 [Print] England
• PMID: 17328233 (Publication Type: Journal Article, Review)

Chemical References

• Anti-Bacterial Agents
• Glycosides
• OPT 80

Topics

• Animals
• Anti-Bacterial Agents (pharmacology, therapeutic use)
• Clinical Trials, Phase II as Topic
• Clinical Trials, Phase III as Topic
• Clostridioides difficile (drug effects, growth & development)
• Diarrhea (drug therapy, microbiology)
• Drug Evaluation, Preclinical
• Enterocolitis, Pseudomembranous (drug therapy, microbiology)
• Glycosides (pharmacology, therapeutic use)
• Humans